Form 8-K CVS HEALTH Corp For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
CVS Health (CVS) PT Lowered to $63 at Deutsche Bank
August 8, 2024 12:31 PM EDTDeutsche Bank analyst George Hill lowered the price target on CVS Health (NYSE: CVS) to $63.00 (from $64.00) while maintaining a Hold rating.
The analyst comments "The Tumult Reaches a New High, as Guidance Reaches a New Low: CVS reported Q2 results and provided an updated earnings outlook with a... More
CVS Health (CVS) cuts full-year EPS guidance on continued pressure in the health care benefits unit
August 7, 2024 6:45 AM EDT(Updated - August 7, 2024 9:56 AM EDT)
CVS Health (NYSE: CVS) reported second-quarter earnings that beat analyst expectations, but shares fell by more than 2% as the company cut its full-year guidance, citing continued pressure in its Health Care Benefits segment.
The healthcare giant reported adjusted earnings per share (EPS) of $1.83 for Q2, surpassing the analyst estimate of $1.73. However, revenue came in at $91.2 billion, slightly below the consensus estimate of $91.43 billion, though it represented a 2.6% increase YoY.
CVS Health revised its full-year 2024 adjusted EPS guidance to a range of $6.40 to $6.65, down from its... More
